Product development and service companies that wish to conduct systematic studies under controlled conditions are welcome to participate with IPS. With an exclusive focus on podiatric medicine, web-based technology, and a nationwide presence, we are uniquely prepared to support product/treatment studies.

One such study is the APMA Walking Study in which IPS is currently participating .  This is a 48 week study including sixteen podiatric practices. Two groups totaling 250 patients from across the United States will be monitored for forty-eight weeks. The IPS technology platform, together with a podiatric focus and unique workflow process was chosen as an optimal way of monitoring this protocol. For more detailed information on the APMA Walking Study, click here.   

Pharmaceutical companies, product R&D departments and service companies who wish to access the IPS Study Program can contact Lori Sklar, COO, at Lsklar@ips-med.com for more information.